Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Blood (2018) 132 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2018-99-114126

Published: 2018

Journal Articles

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Justin Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Shira Dinner, MD, Sangmin Lee, MD, Karen Seiter, MD, Thomas Prebet, MD PhD, Gary J. Schiller, MD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Hagop M. Kantarjian, MD, Patrick Kelly, MD, Ping Li, PhD, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2018-99-114263

Published: 2018

Journal Articles

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, MD, Carlo Gambacorti-Passerini, Stuart L Goldberg, Jorge E. Cortes, H. Jean Khoury, MD, Mauricette Michallet, MD PhD, Ronald Paquette, MD, Bengt Simonsson, MD PhD, Michelle P Turner, MS in Biostatistics, Hesham Mohamed, MD, Milayna Subar, MD, Teresa Zyczynski, Pharm.D., MPH

Blood (2014) 124 (21): 3151.

https://doi.org/10.1182/blood.V124.21.3151.3151

Published: 2014

Journal Articles

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

Neil P. Shah, MD PhD, Philippe Rousselot, MD PhD, Charles A. Schiffer, MD, Delphine Rea, MD PhD, Jorge E. Cortes, MD, Jorge Milone, MD, Hesham Mohamed, MD, Diane Healey, MS, Hagop Kantarjian, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD

Blood (2014) 124 (21): 520.

https://doi.org/10.1182/blood.V124.21.520.520

Published: 2014

Journal Articles

Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study

Blood (2014) 124 (21): 1321.

https://doi.org/10.1182/blood.V124.21.1321.1321

Published: 2014

Journal Articles

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, MD, Rüdiger Hehlmann, MD, Carlo Gambacorti-Passerini, MD, Stuart Goldberg, MD, H. Jean Khoury, MD, Michael Mauro, MD, Mauricette Michallet, MD, PhD, Ron Paquette, MD, PhD, Bengt Simonsson, MD, PhD, Aimee Foreman, PhD, Hesham Mohamed, MD, Teresa Zyczynski, Pharm.D., MPH, Ishan Hirji, MPH, Catherine Davis, Pharm.D.

Blood (2013) 122 (21): 4026.

https://doi.org/10.1182/blood.V122.21.4026.4026

Published: 2013

Journal Articles

The Association Of Dasatinib-Induced Lymphocytosis With Treatment Outcome In Patients With Chronic Myeloid Leukemia (CML)

Charles A. Schiffer, MD, Jorge E. Cortes, MD, Giuseppe Saglio, MD, Philipp D. le Coutre, MD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD, Hesham Mohamed, MD, Neil P. Shah, MD, PhD

Blood (2013) 122 (21): 2741.

https://doi.org/10.1182/blood.V122.21.2741.2741

Published: 2013

Journal Articles

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Jorge E. Cortes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD, Neil P. Shah, MD, PhD, Jiri Mayer, MD, PhD, Philip Rowlings, MD, Hirohisa Nakamae, MD, PhD, M. Brigid Bradley-Garelik, MD, Hesham Mohamed, MD, Hagop M. Kantarjian, MD, Giuseppe Saglio, MD

Blood (2013) 122 (21): 653.

https://doi.org/10.1182/blood.V122.21.653.653

Published: 2013

Journal Articles

Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score

Franck E. Nicolini, MD, PhD, Philippe Rousselot, MD, PhD, Stephane Giraudier, MD, PhD, Gabriel Etienne, MD, PHD, Hyacinthe Johnson-Ansah, MD, Lydia Roy, MD, Pascale Cony-Makhoul, MD, Yann Guillermin, MD, Mohamad Sobh, Pharm.M., Pierre Marie, CRA, Driss Kamar, Biostat, Hesham Mohamed, MD, Denis Caillot, MD, Delphine Rea, MD, PhD

Blood (2013) 122 (21): 383.

https://doi.org/10.1182/blood.V122.21.383.383

Published: 2013

Journal Articles

Evidence for Pulmonary Vascular Disease Despite Absence of Overt Pulmonary Arterial Hypertension (PAH) in Myeloproliferative Disorders (MPD) (PV and ET).

Jean-Jacques Kiladjian, MD, Christine Lamberto, MD, Thierry Laperche, MD, Hilario Nunes, MD, Hesham Mohamed, MD, Dominique Valeyre, MD, Jean-Paul Richalet, MD, Pierre Fenaux, MD

Blood (2005) 106 (11): 4939.

https://doi.org/10.1182/blood.V106.11.4939.4939

Published: 2005

NARROW

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

The Association Of Dasatinib-Induced Lymphocytosis With Treatment Outcome In Patients With Chronic Myeloid Leukemia (CML)

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score

Evidence for Pulmonary Vascular Disease Despite Absence of Overt Pulmonary Arterial Hypertension (PAH) in Myeloproliferative Disorders (MPD) (PV and ET).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only